Ras/Raf/MEK/ERK is a crucial pathway regulating cell cycle progression, apoptosis,
and drug resistance. The Ras oncogene is frequently mutated in human cancer,
which can result in the activation of the downstream Raf/MEK/ERK cascade leading
to cell cycle progression in the absence of a growth stimulus. Raf-induced proliferation
has been observed in hematopoietic cells. However, the mechanisms by which Raf
affects cell cycle progression are not well described. To investigate the importance
of Raf/MEK/ERK signaling in human hematopoietic cell growth, the effects of
three different Raf genes, A-Raf, B-Raf and Raf-1, on cell cycle progression
and regulatory gene expression were examined in TF-1 cells transformed to grow
in response to b-estradiol-regulated DRaf:ER genes. Raf activation increased
the expression of cyclin A, cyclin D, cyclin E, and p21Cip1, which are associated
with G1 progression. Activated DRaf-1:ER and DA-Raf:ER but not DB-Raf:ER increased
Cdk2 and Cdk4 kinase activity. The regulatory role of p16Ink4a, a potent Cdk4
kinase inhibitor, on the kinase activity of Cdk2 and Cdk4 was also examined.
Raf induced p16Ink4a suppressor but this did not eliminate Cdk4 kinase activity.
These results indicate that human hematopoietic cells transformed to grow in
response to activated Raf can be used to elucidate the mechanisms by which various
cell cycle regulatory molecules effect cell cycle progression. Furthermore,
the differences that the various Raf isoforms have on Cdk4 activity and other
cell cycle regulatory molecules can be determined in these cells.
Key Words:
Cell cycle, Raf, p21Cip1, p27Kip1, Cyclins, Cdks, Hematopoietic cells